Evidence map›Paper›PMID 40978043›Full record

ArticleFrontiers in oncology2025

Demographic features and prognostic factors of uterine carcinosarcoma: a study at a specialized center in Saudi Arabia.

Wala Mehros, Sarah Aldosari, Rahaf Alharbi, Wasan Alshareef, Wesal Hawsawi, Halah Fallata, Hatim Aljifree, Alaa Althubaiti

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wala MehrosDepartment of Oncology King Abdul-Aziz Medical City, Ministry of The National Guard Health Affairs, Jeddah, Saudi Arabia.
Sarah AldosariKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Rahaf AlharbiKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Wasan AlshareefKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Wesal HawsawiKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Halah FallataKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Hatim AljifreeDepartment of Oncology King Abdul-Aziz Medical City, Ministry of The National Guard Health Affairs, Jeddah, Saudi Arabia.
Alaa AlthubaitiKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Uterine carcinosarcoma is a rare, aggressive biphasic tumor comprising both carcinomatous and sarcomatous elements. The overall prognosis of women with uterine carcinosarcoma is poor, with a median overall survival of less than two years. The predictors of survival for patients with uterine carcinosarcoma in the Kingdom of Saudi Arabia have not yet been fully elucidated; this study therefore explored the demographic features and prognostic factors of uterine carcinosarcoma. Methods: This A cross-sectional study was conducted among all confirmed carcinosarcoma cases at Princess Noorah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia, from January 2003 to December 2023. Data were collected on demographic features, medical history, stage, treatment modality, and disease outcome. Results: A total of 34 patients with carcinosarcoma were identified, accounting for 4.7% of all endometrial cancer cases. Sixty percent of patients were diagnosed early, during stages 2B and below. The most common presentation was post-menopausal bleeding, occurring in 90% of the sample. Kaplan-Meir analysis revealed an overall median survival of 14 months. Conclusion: The findings confirmed the aggressiveness of the tumor. Late tumor stage was identified as a factor affecting patients' survival and outcome, being associated with poor prognosis and short survival time.

Indexed as

demographicsendometrial neoplasmoverall survivalprognosisuterine carcinosarcoma

Identifiers

PMID40978043
PMCPMC12446034

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.